Behavior of Serous Borderline Ovarian Tumors With and Without Micropapillary Patterns: Results of a French Multicenter Study
- 288 Downloads
Behavior of serous borderline ovarian tumors with micropapillary patterns (MP-SBOT) is thought to be worse than those without micropapillary patterns, but few cohort studies have compared epidemiological characteristics, surgical management, and recurrence rates between these two groups.
In a French retrospective multicenter study of 475 borderline ovarian tumors (BOT) treated from 1990 to 2009, we studied patients with a serous BOT and treated after 2000 including 20 patients with and 77 patients without micropapillary patterns.
Patients with MP-SBOT were younger (P = 0.01), often asymptomatic (P = 0.04), and with abnormal CA 125 serum levels (P = 0.04). Peritoneal implants were more frequently observed in these patients (P = 0.01); also, they underwent conservative treatment more frequently (P = 0.002), had a higher risk of misdiagnosis with invasive carcinoma by intraoperative histology (P < 0.05), and had more frequent restaging surgery (P = 0.001). No difference in recurrence was noted between the groups. No disease-related mortality was observed.
Patients with MP-SBOT represent a heterogeneous population in terms of presence of invasive peritoneal implants. Conservative surgery could be a suitable option for MP-SBOT patients without implants and who wish to conserve childbearing potential, without increasing the risk of recurrence.
The authors thank the participating centers: Centre Hospitalier Universitaire Amiens (Prof. Gondry), Centre Hospitalier Universitaire Angers (Prof. Descamps), Centre de Recherche et de Lutte contre le Cancer Paul Papin Angers (Dr. Fondrinier), Centre Hospitalier Général Le Mans (Dr. Pillot), Centre Hospitalier Universitaire Lille (Prof. Querleu), Centre Hospitalier Universitaire Marseille (Prof. Blanc), Centres Hospitaliers Universitaires Paris: Hôpital Bichat (Prof. Madelenat), Hôpital Cochin (Prof. Chapron), Hôpital de la Pitié-Salpétrière (Prof. Lefranc, Prof. Dommergues), Hôpital Saint Antoine (Prof. Milliez), Hôpital Tenon (Prof. Uzan), Centre Hospitalier Universitaire Reims (Prof. Graesslin), Centre Hospitalier Général Roubaix (Prof. Querleu), Centre Hospitalier Universitaire Rouen (Prof. Marpeau), Institut Gustave Roussy Villejuif (Prof. Morice), and Centre Hospitalier Universitaire Strasbourg (Prof. Baldauf).
- 2.Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand. 1971;50:1–7.Google Scholar
- 15.Tavassoli FA, Devilee P. World Health Organization classification of tumors: pathology and genetics of tumors of the breast and female genital organs. Lyon, France: IARC Press; 2003.Google Scholar
- 23.Faluyi O, Mackean M, Gourley C, Bryant A, Dickinson HO. Interventions for the treatment of borderline ovarian tumours. Cochrane Database Syst Rev. 2010;CD007696.Google Scholar